Correction to: Osteoporos Int
The original version of this article, published on 15 October 2018, unfortunately, contained a mistake.
Table 1 of the paper above stated that the remaining lifetime risk of hip fracture for a woman from Sweden age 80 years was 49.3%. The correct figure should be 19.3%.
Conflict of interest
JAK reports grants from Amgen, Eli Lilly and Radius Health; non-financial support from Medimaps, and Asahi; and other support from AgNovos. JAK is the architect of FRAX® but has no financial interest. CC reports personal fees from Alliance for Better Bone Health, Amgen, EliLilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB. RR has received consulting fees or advisory board fees from Radius Health, Labatec, Danone, Nestlé, CNIEL andSandoz. J-YR has received advisory boardor consulting fees from IBSA-Genévrier, Pierre Fabre, Radius Health, TEVA and Mylan; and lecture fees from Anovos, IBSA-Genévrier, Mylan, CNIEL, Dairy Research Council (DRC) and Theramex; and institutional grant support from IBSA-Genévrier, Mylan, CNIEL and Radius Health.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s00198-018-4704-5
About this article
Cite this article
Kanis, J.A., Cooper, C., Rizzoli, R. et al. Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 31, 209 (2020). https://doi.org/10.1007/s00198-019-05184-3